Literature DB >> 3080467

Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH.

M L Vance, D L Kaiser, J Rivier, W Vale, M O Thorner.   

Abstract

Continuous infusion of human GH-releasing hormone (GHRH) stimulates GH secretion in normal subjects, but a single supramaximal iv dose of GHRH thereafter elicits a diminished serum GH response compared to that after a saline infusion; the response to the single dose challenge is inversely related to the dose of GHRH previously infused. To determine if this attenuated GH response is a result of depletion of available GH or desensitization of the somatotroph, a 6-h infusion of saline or GHRH (10 ng/kg . min) was administered to 10 normal men, and an iv bolus dose of either GHRH (3.3 micrograms/kg) or regular insulin (0.15 U/kg) was given after 5.5 h of infusion. On both days of GHRH infusion, there was significant stimulation of GH secretion compared to that after saline infusion. The GH response to the supramaximal dose of GHRH was greater after saline infusion than after GHRH infusion, and the GH response to insulin-induced hypoglycemia was significantly greater after GHRH infusion compared with the responses on the other 3 study days. The greatest GH secretion occurred during GHRH infusion followed by insulin administration; therefore, pituitary reserve was not decreased by prior exposure to GHRH. These studies suggest that somatotrophs become partially refractory to GHRH stimulation over time, but remain responsive to an alternate stimulus of GH secretion. We suggest that the hypoglycemia-induced GH response occurs via a reduction in hypothalamic somatostatin secretion, and the attenuated GH response to the supramaximal GHRH dose after GHRH infusion probably represents either partial desensitization or down-regulation of the GHRH receptor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080467     DOI: 10.1210/jcem-62-3-591

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Long term growth hormone (GH)-releasing hormone and biosynthetic GH therapy in GH-deficient children: comparison of therapeutic effectiveness.

Authors:  M Bozzola; I Biscaldi; M Cisternino; F Severi; A Balsamo; E Cacciari; C Pellini; G Chiumello; G L Spadoni; B Boscherini
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

2.  GH responsiveness to repeated GHRH or hexarelin administration in normal adults.

Authors:  A Sartorio; A Conti; S Ferrero; A Spada; G Faglia
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

3.  Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses.

Authors:  C A Jaffe; R D Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 4.  Rhythm and blues. Neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders.

Authors:  D Healy
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.

Authors:  C A Jaffe; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

6.  A prospective study of hypothalamus pituitary function after cranial irradiation with or without radiosensitizing chemotherapy.

Authors:  T S Huang; S C Huang; M M Hsu
Journal:  J Endocrinol Invest       Date:  1994-09       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.